Grant: Engage Grants Program
McGill University
$25,000.00
Feasibility of Near-Infrared Spectroscopy as a Process Analytical Tool for Inline/Online Control of Manufacturing of an Omega-3 Phospholipid Concentrate Pharmaceutical Product
EF 2018-19
Résumé
Acasti Pharma is a Quebec-based biopharmaceutical innovator focused on the research and development of*new krill oil-based forms of omega-3 phospholipid therapies for the treatment of cardiometabolic diseases. The*company's lead drug candidate, CaPrer, is a krill oil-derived mixture of polyunsaturated fatty acids (PUFAs),*primarily composed of the omega-3 fatty acids EPA and DHA, which are present as a combination of*phospholipid esters and free fatty acids. For production of the active pharmaceutical ingredient, Acasti Pharma*is among the few innovative pharmaceutical companies to have developed a continuous manufacturing process,*as opposed to traditional batch manufacturing. The company has plans to implement innovative process*analytical technology (PAT) based on near-infrared (NIR) spectroscopy on its production line as a means of*building quality into the manufacturing process. Before investing in this technology, a full assessment of the*information that NIR spectroscopy can provide about each stage in the manufacturing process is required. This*Engage Grant will enable the company to establish a collaboration with a McGill University researcher who*will employ advanced mathematical techniques to analyze the NIR spectroscopic data acquired from samples*taken at six points in the manufacturing process and correlate these data with the concentrations of key*molecular components, as determined by laboratory analyses and by nuclear magnetic resonance (NMR)*spectroscopy. Upon completion of this research, Acasti Pharma will have the critical information needed to*justify the significant capital investment associated with implementation of process analytical technology,*which is an approach to improving the quality of pharmaceutical products that is recognized by Health Canada,*the U.S. FDA, and other regulatory agencies around the world. The company's innovations in manufacturing*will increase its competitiveness in the global marketplace, resulting in the creation of new jobs and stimulating*growth of the biopharmaceutical sector in Canada.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
530992-2018
Name nom
Ismail, Ashraf
Department département
Food Science and Agricultural Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
515
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Instrumentation technology
Area of application fr
Technologie de l'instrumentation
Research subject code
3505
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Analytical spectroscopy
Research subject fr
Spectroscopie analytique
Partie
1
Nb partie
1
Application title
Feasibility of Near-Infrared Spectroscopy as a Process Analytical Tool for Inline/Online Control of Manufacturing of an Omega-3 Phospholipid Concentrate Pharmaceutical Product
Keyword
NSERC
Application summary
Acasti Pharma is a Quebec-based biopharmaceutical innovator focused on the research and development of*new krill oil-based forms of omega-3 phospholipid therapies for the treatment of cardiometabolic diseases. The*company's lead drug candidate, CaPrer, is a krill oil-derived mixture of polyunsaturated fatty acids (PUFAs),*primarily composed of the omega-3 fatty acids EPA and DHA, which are present as a combination of*phospholipid esters and free fatty acids. For production of the active pharmaceutical ingredient, Acasti Pharma*is among the few innovative pharmaceutical companies to have developed a continuous manufacturing process,*as opposed to traditional batch manufacturing. The company has plans to implement innovative process*analytical technology (PAT) based on near-infrared (NIR) spectroscopy on its production line as a means of*building quality into the manufacturing process. Before investing in this technology, a full assessment of the*information that NIR spectroscopy can provide about each stage in the manufacturing process is required. This*Engage Grant will enable the company to establish a collaboration with a McGill University researcher who*will employ advanced mathematical techniques to analyze the NIR spectroscopic data acquired from samples*taken at six points in the manufacturing process and correlate these data with the concentrations of key*molecular components, as determined by laboratory analyses and by nuclear magnetic resonance (NMR)*spectroscopy. Upon completion of this research, Acasti Pharma will have the critical information needed to*justify the significant capital investment associated with implementation of process analytical technology,*which is an approach to improving the quality of pharmaceutical products that is recognized by Health Canada,*the U.S. FDA, and other regulatory agencies around the world. The company's innovations in manufacturing*will increase its competitiveness in the global marketplace, resulting in the creation of new jobs and stimulating*growth of the biopharmaceutical sector in Canada.